The autologous cell therapy market involves the application of a patient's own cells to prevent, treat or cure disease. It involves extracting cells from a patient's body, treating them to increase their therapeutic efficacy and returning them to the same patient. Autologous cell therapies are useful in treating cancer, neurodegenerative disorders and autoimmune diseases. They offer minimal risk of rejection and long-lasting effects as the cells are a patient's own.
The Global Autologous Cell Therapy Market is estimated to be valued at USD 5.51 Bn in 2025 and is expected to reach USD 22.30 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 22.1% from 2025 to 2032.
Key Takeaways
Key players operating in the autologous cell therapy market are Bristol-Myers Squibb Company, JCR Pharmaceuticals Co., Ltd., MEDIPOST Co., Ltd., Orgenesis Inc., and Vericel Corporation.
Autologous Cell Therapy Market opportunities prevalence of cancer globally and increasing R&D investments for developing innovative autologous cell therapies. From 2021 to 2025, cancer cases are expected to rise by almost 28% worldwide. This raises the need for advanced therapeutic options like autologous cell therapies. The market is also witnessing increased global expansion as major players are establishing manufacturing facilities and entering collaborations in emerging regions. For instance, Bristol-Myers Squibb has expanded its autologous cell therapy manufacturing capacity in the Asia Pacific to cater to the unmet cancer needs in the region.
Market Drivers
Rising cancer prevalence is one of the major drivers of the autologous cell therapy market. Globally, cancer burden has been increasing rapidly with an estimated 19.3 million new cancer cases and 10 million cancer deaths reported in 2020. This high disease incidence elevates the demand for individualized treatment approaches like autologous cell therapies. PEST Analysis Political: The regulations pertaining to autologous cell therapy procedures are well defined by bodies like FDA and EMA. However, the regulations differ across countries and regions which impacts the market. Economic: The costs involved in autologous cell therapies are very high as they require specialized infrastructure and skilled labor. However, their ability to cure degenerative diseases reduces long term healthcare costs. Social: With rising awareness, people are willing to opt for autologous cell therapies for treating chronic and degenerative diseases. However, only a section can afford their high costs currently. Technological: The technologies used for processing autologous cells require specialized equipment and trained professionals. Ongoing R&D is bringing advances like automation, which can improve process efficiency and lower costs involved in autologous cell therapy production.
Geographical Regions with Highest Market Concentration North America accounts for the largest share of the global autologous cell therapy market currently, mainly due to presence of advanced healthcare infrastructure and availability of skilled professionals. The United States contributes significantly owing to presence of major market players and supportive regulatory environment for thorough research. Europe is the second largest regional market driven by rising geriatric population and increasing research activities in the area of regenerative medicines.
Fastest Growing Region Asia Pacific region is poised to experience the highest growth over the forecast period owing to increasing healthcare expenditures, rising incidence of chronic diseases, growing medical tourism industry and ongoing infrastructure developments in major countries like China and India. Large patient pool and favorable regulatory assistance for clinical trials are contributing to regional market growth. Initiatives to increase awareness would further aid autologous cell therapy adoption in Asia Pacific.
Get this Report in Japanese Language
Get this Reports in Korean Language
About Author:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
Transparency Market Research (TMR) has published a new report titled, ‘Autologous cell therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
A number of cells are used for cellular therapy treatment procedure such as T cells, stem cells, fibroblast, dendritic cells, chondrocyte etc.
Cells are cultured/engineered and expanded in-vitro and re introduced in the patient’s body for treatment purpose.North America dominated the global autologous cell therapy market in 2018and the trend is anticipated to continue during the forecast period.
Highly structured health care industry, increased usage of autologous cell therapy for treatment of various autoimmune and neurological disorders, and new product launch are expected to drive the market in North America.Asia Pacific is likely to be a highly lucrative market for autologous cell therapy and it is expected to expand at a high CAGR during the forecast periodRequest COVID Analysis on Autologous Cell Therapy Industry Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=715 Rise in Prevalence of Neurological Disorders & Cancer and Others to Drive MarketIncrease in incidence of neurological disorders, cancer and autoimmune disorders are helps to drive the growth of this market during forecasted period.Prevalence of several neurological disorders such as multiple sclerosis, Parkinson's disease, and others are helps to drive the growth of this market during forecasted period.
Bone marrow is the hub for most of the stem cells (major products are bone marrow based) and extensive R activities for bone marrow derived stem cells boost market growth.
High preference and growing demand for bone marrow derived cells are likely to propel the segment in developed regions.Epidermis segment is likely to be a highly lucrative market for autologous cell therapy and it is expected to expand at a high CAGR during the forecast period due to growing preference for stem cells/autosomal cells extracted from the skin as it is the largest organ in the body.Request Customization on Autologous Cell Therapy Industry Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=715 Neurology Segment to be Highly Lucrative SegmentIn terms of application, the global autologous cell therapy market has been classified into branded neurology, orthopedic, cancer, wound healing, cardiovascular disorders, autoimmune disorders and others.The neurology segment dominated the autologous cell therapy market due to high preference for cell therapy products for neurodegenerative diseases, rapid rise of stroke death worldwide, and favorable government support accentuates market growth.The cancer segment is expected to expand at a significant CAGR by 2027.
